Patent ID: 11879005
Assignee: NUMAB THERAPEUTICS AG
Field: Biotechnology (Chemistry)
Classification: CPC A  C | IPC C

Claim 0:
1. A hetero-dimeric protein comprising a first and a second single-chain protein,
wherein said first single-chain protein comprises a first amino acid sequence consisting of (from the N- to the C-terminus):
(ia) a first VL domain;
(iia) a first polypeptide linker and
(iiia) a second VL domain, and
wherein said second single-chain protein comprises a second amino acid sequence consisting of (from the N- to the C-terminus):
(ib) a first VH domain;
(iib) a second polypeptide linker and
(iiib) a second VH domain, and
wherein said first VL domain forms a first cognate pair of variable domains with specificity to a first target antigen with either said first or said second VH domain, and said second VL domain forms a second cognate pair of variable domains with specificity to a second target antigen with the other of said VH domains, and wherein at least one of said first or said second single-chain protein further comprises:
(iv) a third functional domain with specificity to a third target antigen that is fused via a third polypeptide linker to said first or said second amino acid sequence, so that said hetero-dimeric protein is trispecific; and
wherein said hetero-dimeric protein does not comprise (i) a cognate pair of a first and a second immunoglobulin constant domain, wherein said first immunoglobulin constant domain is comprised in said first single-chain protein and wherein said second immunoglobulin constant domain is comprised in said second single-chain protein, and wherein said hetero-dimeric protein does not comprise (ii) any further pair of heteroassociation domains, in which one heteroassociation domain of said further pair of heteroassociation domains is located on the first single-chain protein, and the other heteroassociation domain is located on the second single-chain protein, other than said first and second cognate pairs of variable domains,
wherein at least one of said VL and/or VH domains comprises human framework regions, wherein at least one of said VL domains comprises (i) human Vk framework regions I to III; (ii) CDR domains CDR1, CDR2 and CDR3; and (iii) a framework region IV, which is a human Vλ germ line sequence for framework region IV.